endometriosis, and painful and heavy menstrual periods. Arstat's high-value portfolio is protected by 10 granted U.S. patents (more pending) and a European (EPO) patent.

The pipeline includes 4 drug candidates with proven efficacy and safety. Two products are Phase III-ready (confirmed by the FDA), two other products are ready for Phase IIb. An addressable US market is approximately 50 million women with projected peak US net sales of $3.0 – 4.0 billion. The targeted global market may exceed 800 million women with significant European and worldwide sales.

Arstat's most valuable asset, Nuvocept, is the first and only oral contraceptive designed explicitly for overweight and obese women. The FDA has already endorsed an unprecedented clinical program and a potentially unique label. Nuvocept is expected to dominate a multi-billion-dollar segment of the U.S. contraceptive market

The Founder and CEO of Arstat Pharmaceuticals, Arkady Rubin, has over 30 years of industry experience (J&J, Pfizer) and is the co-inventor of Ortho Tri-Cyclen Lo, the best-selling oral contraceptive in the U.S. with peak sales exceeding $500 million per year.

Arstat is raising a seed financing round to hire key executives, assemble a top-notch Board of Directors ahead of a $50.0 million public offering one year later, potentially in conjunction with a strategic partnership or collaboration. Proceeds raised in the public offering would allow Arstat to advance its Phase III candidates through NDA filing, FDA approval, and sale or out-licensing in 3 - 3.5 years from the initial financing round as well as complete Phase IIb studies for its remaining candidates. Conservative estimates of the fair value of Arstat's product portfolio at the time of the public offering are between $500 – $800 million.